Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis
Background The COVID-19 pandemic has strained health system capacity worldwide due to
a surge of hospital admissions, while mitigation measures have simultaneously reduced …
a surge of hospital admissions, while mitigation measures have simultaneously reduced …
Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy
Pathological complete response (pCR) after neoadjuvant chemotherapy (NCT) is associated
with good long-term prognosis in breast cancer (BC) patients. However, some patients still …
with good long-term prognosis in breast cancer (BC) patients. However, some patients still …
Wait times and breast cancer survival: a population-based retrospective cohort study using CanIMPACT data
Purpose The time from breast cancer surgery to chemotherapy has been shown to affect
survival outcomes; however, the effect of time from first breast cancer-related healthcare …
survival outcomes; however, the effect of time from first breast cancer-related healthcare …
Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients
Purpose The implementation of national breast cancer (BC) screening programs in Latin
America has been rather inconsistent. Instead, most countries have opted for “opportunistic” …
America has been rather inconsistent. Instead, most countries have opted for “opportunistic” …
Isolating the effect of confounding from the observed survival benefit of screening participants—a methodological approach illustrated by data from the German …
L Buschmann, I Wellmann, N Bonberg, J Wellmann… - BMC medicine, 2024 - Springer
Background Mammography screening programmes (MSP) aim to reduce breast cancer
mortality by shifting diagnoses to earlier stages. However, it is difficult to evaluate the …
mortality by shifting diagnoses to earlier stages. However, it is difficult to evaluate the …
Human study on cancer diagnostic probe (CDP) for real‐time excising of breast positive cavity side margins based on tracing hypoxia glycolysis; checking diagnostic …
Background Cancer diagnostic probe (CDP) had been developed to detect involved breast
cavity side margins in real‐time (Miripour et al. Bioeng Transl Med. e10236.). Here, we …
cavity side margins in real‐time (Miripour et al. Bioeng Transl Med. e10236.). Here, we …
[HTML][HTML] Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple …
Background Breast cancer (BC) is the leading cause of cancer death for Chilean women.
About 11% of cases are triple-negative (TN) BC. These are characterised by poor prognosis …
About 11% of cases are triple-negative (TN) BC. These are characterised by poor prognosis …
The contribution of second primary cancers to the mortality of patients with a first primary breast cancer
E Gonçalves, F Fontes, JR Rodrigues, R Calisto… - Breast Cancer Research …, 2024 - Springer
Abstract Purpose Second primary cancers (SPCs) are estimated to affect nearly 5% of
patients with breast cancer within 10 years of their diagnosis. This study aimed to estimate …
patients with breast cancer within 10 years of their diagnosis. This study aimed to estimate …
Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study
Purpose The incidence of breast cancer in young women (BCYW) has increased in recent
decades. Malignant disease in this subset is characterized by its aggressiveness and poor …
decades. Malignant disease in this subset is characterized by its aggressiveness and poor …
[HTML][HTML] Palbociclib in advanced stage hormone receptor-positive breast cancer: real-world data from a Chilean multicentre registry
B Walbaum, JM Reyes, P Rodriguez… - …, 2023 - ncbi.nlm.nih.gov
Background The addition of cyclin-dependent kinases inhibitors (CDKi) to endocrine therapy
(ET) as the first-or second line treatment improves progression-free and overall survival (OS) …
(ET) as the first-or second line treatment improves progression-free and overall survival (OS) …